Abstract 7200: Efficacy of Baxdrostat for Control of Treatment-Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials
Abstract
Background: Hypertension is one of the primary contributors to the global burden of non-communicable diseases. Individuals who maintain blood pressure levels above the target range, despite being on maximally tolerated doses of three or more different classes of antihypertensive drugs, are classified as treatment-resistant hypertension. This systematic review and meta-analysis will explore the efficacy and safety of baxdrostat, an aldosterone synthase inhibitor, in treatment-resistant hypertension. Methods: A systematic search was performed from inception to September 15, 2025. Quantitative synthesis was performed using Review Manager software (version 5.4). Continuous outcomes were reported as mean difference (MD) and dichotomous outcomes were reported as risk ratio (RR), along with their 95% confidence intervals (CI). Results: Four randomized controlled trials (RCTs) were included. For systolic blood pressure (SBP), baxdrostat demonstrated a statistically significant reduction in both 1 mg and 2 mg doses (MD: -6.19, P = 0.010; MD: -7.90, P < 0.00001, respectively). For diastolic blood pressure (DBP), baxdrostat demonstrated a statistically significant reduction in both 1 mg and 2 mg doses (MD: -2.66, P = 0.03; MD: -3.12, P = 0.004, respectively). Baxdrostat was associated with increased risk of any adverse events in both doses (RR: 1.23, P = 0.004; RR: 1.23, P = 0.04, respectively), but no differences were observed for severe adverse events. Importantly, hyperkalemia was significantly associated in both 1 mg and 2 mg doses (RR: 4.43, P = 0.0007; RR: 5.68, P = 0.04, respectively). Conclusion: In conclusion, baxdrostat significantly lowers SBP and DBP in treatment-resistant hypertension at all doses. In terms of safety profile, baxdrostat was associated with any adverse events, including hyperkalemia, at both doses, but not related to severe adverse events. This novel class represents a promising therapeutic advancement, although further phase III trials are needed to arrive at a valid conclusion.